2021 Online, In the cloud


Keynote Lecture COVID-19
Thursday 13:55-14:40
A-01
Welcome and introduction
Thursday 13:00-13:10
A-02
Keynote Lectures COVID-19
Thursday 13:10-14:40
A-03 France Mentré
Pharmacometrics to support clinical investigation during COVID-19 pandemics
Thursday 13:10-13:55
A-03 Jeremie Guedj
Pharmacometrics to support clinical investigation during COVID-19 pandemics : a viral dynamics perspective
Thursday 13:10-13:55
A-04 Thorsten Lehr
Modeling and Simulation of SARS-CoV-2 Infections, Hospitalizations and Outcome in Germany
Thursday 13:55-14:40
A-05
Social break
Thursday 14:40-15:40
A-06
PAGE scientific program
Thursday 15:40-15:45
A-07
Pharmacometrics to advance management and prevention of COVID-19
Thursday 15:45-16:45
A-08 Nadege Neant
Modeling SARS-CoV-2 viral kinetics in hospitalized patients
Thursday 15:45-16:05
A-09 Mélanie Prague
Using population approach to model COVID-19 epidemics in France: estimating the burden of SARS-Cov-2 and the effects of non-pharmaceutical interventions.
Thursday 16:05-16:25
A-10 Seth Robey
Predictive Primates: Enabling Rapid Go/No-Go Decisions on COVID-19 Vaccine Candidates with a Predictive, Translational MBMA and Clinical Immunogenicity Data
Thursday 16:25-16:45
A-11
Break
Thursday 16:45-16:55
A-12
Tutorial
Thursday 16:55-17:40
A-13 Andrew Hooker
Tutorial on survival analysis and its application to the assessment of competing risks in clinical data analysis.
Thursday 16:55-17:10
A-14 Joachim Grevel
Tutorial on application of survival analysis to the assessment of multiple state models in clinical data analysis.
Thursday 17:10-17:40
A-15
Day End
Thursday 17:40
B-01
Poster Session I
Friday 12:00-13:00
B-02
Lewis Sheiner Student Session 2020
Friday 13:00-14:20
B-03 Rob van Wijk
Translational quantitative systems pharmacology; crossing borders between experimental and computational drug development using zebrafish as model organism
Friday 13:00-13:25
B-04 Eleni Karatza
Machine-Learning for cancer treatment: Guided covariate selection for TTE models developed from real world data with a small number of patients
Friday 13:25-13:50
B-05 Vincent Chang
In silico assessment of adaptive trial design for TB regimen development
Friday 13:50-14:15
B-06
Presentation Lewis Sheiner Student Session Awards 2020
Friday 14:15-14:20
B-07
Announcement WCOP 2022
Friday 14:20-14:30
B-08
Social Break
Friday 14:30-15:30
B-09
Lewis Sheiner Student Session 2021
Friday 15:30-16:45
B-10 Linda Aulin
Model-based design of innovative treatment strategies to suppress antimicrobial resistance using collateral sensitivity
Friday 15:30-15:55
B-11 Marion Kerioui
Bayesian modelling of individual lesions dynamics and survival to characterize response to immunotherapy cancer treatments
Friday 15:55-16:20
B-12 Anna Mc Laughlin
Population quantitative systems pharmacology model of distinct CAR-T cell phenotypes and CD19-specific metabolic tumour volume reveals sources of high pharmacokinetic variability and overall survival
Friday 16:20-16:45
B-13
Presentation Lewis Sheiner Student Session Awards 2021
Friday 16:45-16:50
B-14
Break
Friday 16:50-17:00
B-15
Stuart Beal Methodology Session I
Friday 17:00-17:40
B-16 Alexander Janssen
The Neural Mixed Effects algorithm: leveraging machine learning for pharmacokinetic modelling
Friday 17:00-17:20
B-17 James Lu
Deep Learning for PK/PD and Disease Progression Time-Course Predictions using Neural-ODE
Friday 17:20-17:40
B-18
Day End
Friday 17:40
C-01
Poster Session II
Monday 12:00-13:00
C-02
Keynote Lecture
Monday 13:00-13:45
C-03 Vladimir Dragalin
Adaptive trial designs: opportunities and challenges
Monday 13:00-13:45
C-04
Break
Monday 13:45-13:50
C-05
Oncology-dedicated to Laurent Claret
Monday 13:50-15:00
C-06
In Memoriam Laurent Claret
Monday 13:50-14:00
C-07 Anyue Yin
Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
Monday 14:00-14:20
C-08 Sreenath M Krishnan
Multistate model for pharmacometric analyses of overall survival in anticancer treatments
Monday 14:20-14:40
C-09 René Bruno
Operating characteristics of tumor growth inhibition-overall survival models to support early Phase Ib decisions: An evaluation in first-line metastatic non-small cell lung cancer patients treated with atezolizumab plus chemotherapy based on the Phase III study IMpower150
Monday 14:40-15:00
C-10
Social Break
Monday 15:00-16:00
C-11
Integrating machine learning & quantitative pharmacology
Monday 16:00-17:00
C-12 Verena Gotta
Personalizing hemodialysis (HD) treatment in pediatric patients with end-stage renal disease (ESRD) – application and integration of quantitative pharmacology with machine learning
Monday 16:00-16:20
C-13 Jasmine Hughes
A hybrid machine learning/pharmacokinetic approach improves predictive performance in model-informed precision dosing
Monday 16:20-16:40
C-14 Diego Vera
Semi-mechanistic modeling of tumor size and overall survival including machine learning-derived tumor heterogeneity
Monday 16:40-17:00
C-15
Break
Monday 17:00-17:05
C-16
Improving decision making in drug development and clinical care
Monday 17:05-17:45
C-17 Nicolás Marco Ariño
The broad use of pharmacometrics in patient care: the case of blood transfusion and perioperative management
Monday 17:05-17:25
C-18 Estelle Yau
A systematic framework for the incorporation of preclinical species data into physiologically-based pharmacokinetic models using a middle-out approach to improve the translation of drug distribution in humans
Monday 17:25-17:45
C-19
Day End
Monday 17:45
D-01
Poster Session III
Tuesday 12:00-13:00
D-02
Stuart Beal Methodology Session II
Tuesday 13:00-14:00
D-03 Carolina Llanos-Paez
Use of item-based non-linear mixed effects model to improve confidence in Phase III clinical trial decision-making
Tuesday 13:00-13:20
D-04 Iris Minichmayr
Beyond disease progression – Item response theory modelling to gain structural insights into disease facets underlying clinical score assessments
Tuesday 13:20-13:40
D-05 Alexandra Lavalley-Morelle
Individual dynamic predictions in joint analysis for nonlinear marker evolution and competing risk data: application on patients admitted in Intensive Care Unit for sepsis
Tuesday 13:40-14:00
D-06
Break
Tuesday 14:00-14:20
D-07
Bacterial Diseases
Tuesday 14:20-15:30
D-08
In Memoriam Hartmut Derendorf
Tuesday 14:20-14:30
D-09 Zoe Kane
Development of a neonatal plasma and cerebrospinal fluid (CSF) population PK model for fosfomycin.
Tuesday 14:30-14:50
D-10 David Busse
Body composition and drug exposure in adipose tissue are key for antibiotic dose-individualisation in obese individuals
Tuesday 14:50-15:10
D-11 Jérémy Seurat
Combination of in vivo phage therapy data with in silico model highlights key parameters for treatment efficacy
Tuesday 15:10-15:30
D-12
Social Break
Tuesday 15:30-16:15
D-13
Other infectious & Neurological Diseases
Tuesday 16:15-17:15
D-14 Roeland Wasmann
A pharmacometric approach to optimise Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide for children with tuberculosis
Tuesday 16:15-17:35
D-15 Marie Alexandre
Dynamics of the humoral immune response to a two-dose heterologous vaccine regimen against Ebola virus.
Tuesday 16:35-16:55
D-16 João Abrantes
Model-informed development of RG6102, an amyloid-targeting investigational drug with enhanced brain penetration properties
Tuesday 16:55-17:15
D-17
Closing Remarks
Tuesday 17:15-17:25
D-18
Audience Input PAGE 2022
Tuesday 17:25-17:40